Chitosan Derivative-based Hemostat: Irritation, Hypersensitivity and Absorbability Study

Boonlom THAVORNYUTIKARN¹, Wasana KOSORN¹, Pairoj SURATTANAWANICH², Udomsak WONGPARAMI³, and Wanida JANVIKUL^{1*}

¹National Metal and Materials Technology Center, Pathumthani 12120 Thailand ²Department of Surgery, Angthong Hospital, Angthong 14000 Thailand ³Department of Medicine, Angthong Hospital, Angthong 14000 Thailand

Abstract

The objective of this study was to evaluate the safety of a carboxymethylchitosan-based hemostatic prototype for internal use, in terms of irritation, hypersensitivity and absorbability. Skin irritation and delayed-type hypersensitivity tests of the prototype in humans (n=30) were assessed by a patch test method. The human skin sites were graded and photographed after patch removal at each time point using a 4-point (0-3+) grading scale of increasing irritation related to ISO 10993-10:2002(E) and a 6-point grading scale of increasing allergy related to International Contact Dermatitis Research Group (ICDRG). The results demonstrated that the chitosan derivative-based hemostat did not cause skin irritation and delayed-type hypersensitivity on the tested humans' skin. The absorbability of the hemostatic prototype was evaluated in the surgical treatment of penile paraffinoma in ten patients, which was conducted at Angthong Hospital, using a scrotal flap method. This method normally involved two surgical stages. In the first stage, two prototype specimens (2.5 cm x 2.5 cm x 0.20 cm) were implanted inside a patient's treated area until the second operation was performed, normally in three months. The clinical results revealed that, after the whole treatment, no remaining specimens were physically observed. Furthermore, the histological results of the tissues where the specimens had been implanted showed no sample residues, indicating that the chitosan derivative-based hemostat was completely absorbed within three months.

Key words : Clinical, Chitosan Derivative-based Hemostat, Irritation, Hypersensitivity, Absorbability

Introduction

Carboxymethylchitosan, a water-soluble derivative of chitosan, was proved to be non-cytotoxic, biocompatible, and biodegradable.^(1,2) It has found various uses in biomedical applications, particularly as wound healing and hemostatic materials.^(3,4,5) In our previous study, both in vitro and in vivo hemostatic abilities of a carboxymethylchitosan-based hemostatic prototype were assessed with respect to that of a commercial material, SPONGOSTAN[®] Standard. The results revealed that the prototype could significantly shorten the whole blood clotting time (WHBCT), p < 0.05, with a hemostatic efficacy comparative to that of SPONGOSTAN® Standard.⁽³⁾ In the animal trial, the prototype, however, stopped the bleeding from the transected rat tails more effectively than SPONGOSTAN® Standard.⁽⁶⁾Furthermore, the wound healing efficacy and resorbability of the prototype were also evaluated in rats. Nevertheless,

few studies on biological safety of this chitosan derivative in both *in vitro* and in *vivo* models were reported.^(7,8) Moreover, the degradation and absorbability of carboxymethylchitosan-based products in the human body have rarely been reported, especially in hemostatic application.

The objective of this study was, therefore, to clinically evaluate the safety of the carboxymethylchitosan-based hemostatic prototype for internal use, in terms of skin irritation and hypersensitivity and absorbability. Skin irritation and delayed-type hypersensitivity was assessed by using a patch test, whereas the absorbability of the hemostatic prototype was examined in the surgical treatment of penile paraffinoma in ten patients who had sclerosing lipogranuloma. The degradability and absorbability of the implanted prototype were investigated by visual observation and histopathological examination of the surrounding tissues.

Materials and Experimental Procedures

Materials and Methods

The studies on the skin irritation and delayedtype hypersensitivity and absorbability of the hemostatic prototype were approved by the Independent Ethics Committees of Angthong Hospital, No.AEC.001/53 and No.AT.0027.2025/001, respectively. The trials were conducted during April 2010-February 2012. The consent forms were signed by the patients upon their enrollment in the trials.

Preparation of Carboxymethylchitosan-based Hemostatic Prototype

Briefly, highly viscous aqueous solution of carboxymethylchitosan-based hemostat was poured into molds with a given dimension and subsequently lyophilized to produce sponge-like pads. The water-soluble sponges were then individually immersed into gently stirred 10 wt% aqueous calcium chloride solution for 30 min to produce the water-insoluble pads. Afterwards, the pads were removed and successively washed with deionized (DI) water. The resulting pads were ultimately freeze-dried to yield chitosan derivativebased hemostatic prototype which was sterilized by ethylene oxide gas prior to use.

Human Skin Irritation and Delayed-type Hypersensitivity study

Carboxymethylchitosan-based hemostatic prototype (2.5 cm x 2.5 cm x 0.15 cm) was wetted with DI water (0.4 ml). Two controls were employed: gauze (2.5 cm x 2.5 cm x 0.3 cm) wetted with DI water (0.4 ml), as a negative control, and gauze wetted with 15%w/v sodium dodecyl sulfate (SDS) (0.4 ml), as a positive control. The human skin allergic and irritant patch test was conducted in 30 healthy volunteers (17 females and 13 males, aged 24-68 years). All three test samples were applied to each volunteer's upper outer-arm with the duration of exposure to the test samples increasing progressively from 1, 2, 3, 4, 24, 48 to 72 hours. The skin reactions (erythema and oedema) were graded after patch removal at each time point using a 4-point (0-3+) grading scale of increasing irritation related to ISO 10993-10: $2002(E)^{(9-10)}$ and a 6-point grading scale of increasing allergy related to International Contact Dermatitis Research Group (ICDRG). The acquired data were

statistically analyzed using a paired t-test, and p < 0.001 was significantly considered.

Degradability and Absorbability Study

The degradability and absorbability of the carboxymethylchitosan-based hemostatic prototype was examined in the surgical treatment of penile paraffinoma in ten (male) patients aged 18-60 years using a scrotal flap method. They were referred with different acute symptoms after injection of foreign substances, i.e., Vaseline or olive oil, into penises for the purpose of augmentation. Generally, at surgical reconstruction, complete excision of the involved penile skin was performed, followed by skin substitution from the existing and saved coat of the penis. Two pieces of the hemostatic prototype (2.5 cm x 2.5 cm x 0.20 cm) were implanted at the right and left scrotum flaps of the penis and left inside the body until the second operation which was in about three months. The implant surrounding tissues were subsequently sampled and sent out to HI-TECH LAB Co. Ltd (Sala Daeng, Bangkok, Thailand) for histopathological examination and interpretation.

Results and Discussions

Skin Irritation and Delayed-type Hypersensitivity of the Hemostatic Prototype

The clinical results of human skin irritation and delayed-type hypersensitivity of the carboxymethylchitosan-based hemostatic prototype assessed by using a 4-point grading scale of increasing irritation and a 6-point grading scale of increasing allergy are revealed in Table 1. It was found that 29 of 30 volunteers had irritant and allergic skin reactions to the gauze wetted with 15%SDS (positive control) at 72 h, whereas there was no irritant and allergic skin reactions to the gauze wetted with DI water (negative control) and hemostatic prototype in all tested volunteers at 1-72 hours. In addition, the percentages of cumulative skin irritation reaction to 15%SDS (positive control) at 4, 24, 48 and 72 hours were 10.00%, 83.33%, 90.00% and 96.67%, respectively.

Exposure time (h)	Number of irritated subjects (%Cumulative skin irritation)			
	Carboxymethylchitosan-	Positive	Negative	
	based hemostatic	control	control	
	prototype	(gauze	(gauze	
		wetted with	wetted	
		15% SDS)	with	
			DI water)	
1	0(0%)	0(0%)	0(0%)	
2	0(0%)	0(0%)	0(0%)	
3	0(0%)	0(0%)	0(0%)	
4	0(0%)	3(10.00%)	0(0%)	
24	0(0%)	25(83.33%)	0(0%)	
48	0(0%)	27(90.00%)	0(0%)	
72	0(0%)	29(96.67%)	0(0%)	

Table 1. The percentage of cumulative irritation of various materials at different exposure times.

As shown in Table 2, the mean irritant grading scales of the carboxymethylchitosan-based hemostatic prototype were statistically signifycantly different from those of the positive control group (p < 0.001) at 24, 48 and 72 hours. These results designated that carboxymethylchitosanbased hemostat was safe for clinical use in humans as it did not induce any skin irritation and delayed-type hypersensitivity.

 Table 2. Statistical comparison between carboxymethylchitosan-based hemostat and positive control.

Race comparison	p-value
hemostatic prototype versus positive control (4 h)	0.083
hemostatic prototype versus positive control (24 h)	0.000*
hemostatic prototype versus positive control (48 h)	0.000*
hemostatic prototype versus positive control (72 h)	0.000*
*m < 0.001	

*p< 0.001

Absorbability of the Hemostatic Prototype

As vividly revealed in Figure 1, after the chitosan derivative-based hemostatic prototype had been implanted at the right and left scrotum flaps of the patient's penis for three months, both pieces

of the prototype specimens were absolutely degraded. No trace of specimens was visually found.



Figure 1. Photograph of the penile sites where two prototype specimens had been implanted for three months.

The results on histopathological analysis of tissue biopsies before and after implantation of the prototype are shown in Figure 2. Figure 2(a) illustrates the biopsied penile tissue before implantation. It was found that there was intradermal infiltration of mononuclear inflammatory cells and numerous vacuoles (coded as V) of various sizes in the dermal tissue. Numerous epithelioid histiocytes were extensively observed. Furthermore, the spaces were surrounded by multinucleated giant cells (coded as M), similar to the diagnosis of testicular sclerosing lipogranuloma reported previously.⁽¹¹⁾ The histopathological photomicrographs of the biopsied tissue after implantation are shown in Figure 2(b); benign fibrovascular (coded as BF) and adipose tissue existed. There were scattered small blood vessels with mild mononuclear leukocytic infiltrates and focal aggregates of multinucleated gaint cells. Moreover, the inflammatory cells with a lipoid granuloma that was the same type of cells found in the biopsied tissue before implantation was also present. This was likely that the penile paraffinomas were not completely excised during the first surgical stage of the scrotal flap method. However, no foreign body material and inflammation of the tissues were observed. These results suggested that carboxymethylchitosan-based hemostatic prototype did not induce foreign bodies and inflammation of the tissues upon degradation and was ultimately absorbable. The histopathological photomicrographs of the biopsied tissues after implantation from all ten patients were virtually identical; no foreign body material was found.



Figure 2. Histopathological photomicrographs of penile tissues: (a) before and (b) after implantation of tested specimens, original magnification x200 (V = vacuole, M = multinucleated gaint cells, and BF = benign fibrovascular).

Conclusions

The safety of carboxymethylchitosan-based hemostatic prototype for internal use was assessed. The results of this study clearly demonstrated that the prototype did not cause skin irritation reactions to all thirty volunteers throughout the 72-h patch test. The mean irritant grading scales of hemostatic prototype were statistically significantly different from those of the positive control group (p<0.001) at 24, 48 and 72 h. In addition, the implantation results revealed that the hemostatic prototype was completely decomposed within 3 months in the penises of all ten patients who had Vaseline or olive oil induced sclerosing lipogranuloma. No foreign body materials and inflammation of the tissues were noticed.

Acknowledgment

This research was financially supported by National Metal and Materials Technology Center. The authors would also like to thank the nurses at the Department of Surgery and Department of Medicine, Angthong Hospital, Angthong, for their assistance throughout these clinical studies.

References

- Muzzarelli, R.A.A. (1988). Carboxymethylated chitins and chitosans. *Carbohydr Polym.* 8 : 1-21.
- Janvikul, W., Uppanan, P., Thavornyutikarn, B., Prateepasen, R. and Swasdison, S. (2007). Fibroblast interaction with carboxymethylbased hydrogel. *J. Mater. Sci.: Mater. Med.* 18(5): 943-949.

- 3. Janvikul, W., Uppanan, P., Thavornyutikarn, B., Krewraing, J. and Prateepasen, R. (2006). *In vitro* comparative haemostatic studies of chitin, chitosan, and their derivatives. *J. Appl. Polym. Sci.* **102** : 445-451.
- Jayakumar, R., Prabaharan, M., Nair, S.V., Tokura,S., Tamura, Selvamurugan,H. N. (2010). Novel carboxymethyl derivatives of chitin and chitosan materials and their biomedical applications. *Prog. Mater. Sci.* 55: 675-709.
- Angspatt, A., Taweerattanasil, B., Janvikul, W., Chokrungvaranont, P. and Sirimaharaj, W. (2011). Carboxymethylchitosan, alginate and tulle gauze wound dressing : a comparative study in the treatment of partial-thicknees wounds. *Asian Biome-dicine*. 5(3) : 413-416.
- 6. Janvikul, W., Uppanan, P., Kosorn, W., Phulsuksombati, D. and Prateepasen, R. (2006). Evaluation of efficacy of chitosan derivative based hemostat : *In Vitro* and *In Vivo* studies. *The 2nd International Symposium on Biomedical Engineering* (ISBME2006):281-283.
- 7. Chang, J., Liu, W., Han, B. and Liu, B. (2008). The evaluation on biological properties of carboxymethyl-chitosan and carboxymethyl-chitin. J. Ocean Univ. China (English Edition) **7(4)** : 404-410.
- 8. Zheng, M., Han, B., Yang, Y. and Liu, W. (2011). Synthesis, characterization and biological safety of O-carboxymethyl chitosan used to treat Sarcoma 180 tumor. *Carbohydr. Polym.* **86** : 231-238.
- International Organization for Standardization. (2002). Biological evaluation of medical devices - Part 10 : Tests for irritation and delayed-type hypersen-sitivity. *International Standard*. **ISO 10993-10** : 10-49.
- York, M., Grilfiths, H.A., Whittle, E. and Basketter, D.A. (1996). Evaluation of a human patch test for the identification and classification of skin irritation potential. *Contact Dermatitis*. 4 : 202-212.
- Ricchiuti, V.S., Richman, M.B., Haas, C.A., Desai, D. and Cai, D.X. (2002). Sclerosing lipogranuloma of the testis. *Urology*. 60(3): 515.